Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-29T12:00:54.139Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical and economic outcomes attributable to carbapenem-resistant Enterobacterales and delayed appropriate antibiotic therapy in hospitalized patients

Published online by Cambridge University Press:  02 November 2021

Kirati Kengkla Open the ORCID record for Kirati Kengkla [Opens in a new window] ,
Yuttana Wongsalap Open the ORCID record for Yuttana Wongsalap [Opens in a new window] ,
Natthaya Chaomuang Open the ORCID record for Natthaya Chaomuang [Opens in a new window] ,
Pichaya Suthipinijtham ,
Peninnah Oberdorfer  and
Surasak Saokaew Open the ORCID record for Surasak Saokaew [Opens in a new window]
Kirati Kengkla
Affiliation:
Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
Yuttana Wongsalap
Affiliation:
Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
Natthaya Chaomuang
Affiliation:
Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand
Pichaya Suthipinijtham
Affiliation:
Pfizer (Thailand) Limited, Bangkok, Thailand Boehringer Ingelheim (Thai) Limited, Bangkok, Thailand
Peninnah Oberdorfer
Affiliation:
Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Mueang, Chiang Mai, Thailand
Surasak Saokaew*
Affiliation:
Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Unit of Excellence on Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand Biofunctional Molecule Exploratory Research Group, Biomedicine Research Advancement Centre, School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor Darul Ehsan, Malaysia Novel Bacteria and Drug Discovery Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor Darul Ehsan, Malaysia
*
Author for correspondence: Surasak Saokaew, E-mail: [email protected] or [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To assess the impact of carbapenem resistance and delayed appropriate antibiotic therapy (DAAT) on clinical and economic outcomes among patients with Enterobacterales infection.

Methods:

This retrospective cohort study was conducted in a tertiary-care medical center in Thailand. Hospitalized patients with Enterobacterales infection were included. Infections were classified as carbapenem-resistant Enterobacterales (CRE) or carbapenem-susceptible Enterobacterales (CSE). Multivariate Cox proportional hazard modeling was used to examine the association between CRE with DAAT and 30-day mortality. Generalized linear models were used to examine length of stay (LOS) and in-hospital costs.

Results:

In total, 4,509 patients with Enterobacterales infection (age, mean 65.2 ±18.7 years; 43.3% male) were included; 627 patients (13.9%) had CRE infection. Among these CRE patients, 88.2% received DAAT. CRE was associated with additional medication costs of $177 (95% confidence interval [CI], 114–239; P < .001) and additional in-hospital costs of $725 (95% CI, 448–1,002; P < .001). Patients with CRE infections had significantly longer LOS and higher mortality rates than patients with CSE infections: attributable LOS, 7.3 days (95% CI, 5.4–9.1; P < .001) and adjusted hazard ratios (aHR), 1.55 (95% CI, 1.26–1.89; P < .001). CRE with DAAT were associated with significantly longer LOS, higher mortality rates, and in-hospital costs.

Conclusion:

CRE and DAAT are associated with worse clinical outcomes and higher in-hospital costs among hospitalized patients in a tertiary-care hospital in Thailand.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 10 , October 2022 , pp. 1349 - 1359
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Antimicrobial resistance. World Health Organization website. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Published 2020. Accessed October 15, 2021.Google Scholar
Xu, Y, Gu, B, Huang, M, et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000–2012 in Asia. J Thorac Dis 2015;7:376–385.Google ScholarPubMed
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–1602.CrossRefGoogle Scholar
Jee, Y, Carlson, J, Rafai, E, et al. Antimicrobial resistance: a threat to global health. Lancet Infect Dis 2018;18:939–940.Google ScholarPubMed
Jonas, OB, Irwin, A, Berthe, FCJ, Le Gall, FG, Marquez, P. Drug-resistant infections: a threat of our economic future. http://documents.worldbank.org/curated/en/323311493396993758/final-report. Published 2017. Accessed October 13, 2021Google Scholar
Gupta, N, Limbago, BM, Patel, JB, Kallen, AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60–67.CrossRefGoogle Scholar
Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). Centers for Disease Control and Prevention website. https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. Published 2015. Accessed October 13, 2021.Google Scholar
Brolund, A, Lagerqvist, N, Byfors, S, et al. Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill 2019;24:1900123.CrossRefGoogle ScholarPubMed
Bonine, NG, Berger, A, Altincatal, A, et al. Impact of delayed appropriate antibiotic therapy on patient outcomes by antibiotic resistance status from serious gram-negative bacterial infections. Am J Med Sci 2019;357:103–110.CrossRefGoogle ScholarPubMed
Lodise, TP, Zhao, Q, Fahrbach, K, Gillard, PJ, Martin, A. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? BMC Infect Dis 2018;18:625.Google ScholarPubMed
Zilberberg, MD, Nathanson, BH, Sulham, K, Fan, W, Shorr, AF. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study. Antimicrob Resist Infect Control 2017;6:124.Google ScholarPubMed
Martin, A, Fahrbach, K, Zhao, Q, Lodise, T. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: results of a systematic literature review and meta-analysis. Open Forum Infect Dis 2018;5:ofy150.Google ScholarPubMed
Lodise, TP, Berger, A, Altincatal, A, et al. Antimicrobial resistance or delayed appropriate therapy—does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenem-susceptible Enterobacteriaceae? Open Forum Infectious Diseases 2019;6:ofz194.Google ScholarPubMed
Falcone, M, Bassetti, M, Tiseo, G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae . Crit Care 2020;24:29.CrossRefGoogle ScholarPubMed
Zilberberg, MD, Nathanson, BH, Sulham, K, Fan, W, Shorr, AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 2017;17:279.CrossRefGoogle ScholarPubMed
Molton, JS, Tambyah, PA, Ang, BS, Ling, ML, Fisher, DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis 2013;56:1310–1318.Google ScholarPubMed
Chotiprasitsakul, D, Srichatrapimuk, S, Kirdlarp, S, Pyden, AD, Santanirand, P. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary-care hospital. Infect Drug Resist 2019;12:461–468.CrossRefGoogle ScholarPubMed
de Maio Carrilho, CM, de Oliveira, LM, Gaudereto, J, et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 2016;16:629.Google ScholarPubMed
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 30th edition. CLSI supplement M100. Wayne, PA: CLSI; 2020.Google Scholar
Magiorakos, AP, Srinivasan, A, Carey, RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–281.CrossRefGoogle Scholar
Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.CrossRefGoogle ScholarPubMed
Siegman-Igra, Y, Fourer, B, Orni-Wasserlauf, R, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002;34:1431–1439.CrossRefGoogle ScholarPubMed
Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.Google ScholarPubMed
Tamma, PD, Aitken, SL, Bonomo, RA, Mathers, AJ, van Duin, D, Clancy, CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2021;72:1109–1116.Google Scholar
Consumer Price Index of the Northern Region. Bank of Thailand website. https://www.bot.or.th/App/BTWS_STAT/statistics/BOTWEBSTAT.aspx?reportID=880&language=ENG. Accessed October 13, 2021.Google Scholar
Rates of Exchange of Commercial Banks in Bangkok Metropolis (2002-present). Bank of Thailand website. https://www.bot.or.th/App/BTWS_STAT/statistics/ReportPage.aspx?reportID=123&language=eng. Accessed October 13, 2021.Google Scholar
Schober, P, Vetter, TR. Survival analysis and interpretation of time-to-event data: the tortoise and the hare. Anesthesia Analgesia 2018;127:792–798.Google ScholarPubMed
Zhang, Z, Reinikainen, J, Adeleke, KA, Pieterse, ME, Groothuis-Oudshoorn, CGM. Time-varying covariates and coefficients in Cox regression models. Ann Translat Med 2018;6:11.Google Scholar
Mihaylova, B, Briggs, A, O’Hagan, A, Thompson, SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ 2011;20:897–916.Google ScholarPubMed
Nour, I, Eldegla, HE, Nasef, N, Shouman, B, Abdel-Hady, H, Shabaan, AE. Risk factors and clinical outcomes for carbapenem-resistant gram-negative late-onset sepsis in a neonatal intensive care unit. J Hosp Infect 2017;97:52–58.Google Scholar
Huang, W, Qiao, F, Zhang, Y, et al. In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis 2018;67:S225–S230.Google Scholar
Huang, AM, Newton, D, Kunapuli, A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013;57:1237–1245.Google ScholarPubMed
Tumbarello, M, Trecarichi, EM, De Rosa, FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133–2143.CrossRefGoogle Scholar
Falagas, ME, Tansarli, GS, Karageorgopoulos, DE, Vardakas, KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 2014;20:1170–1175.Google ScholarPubMed
Wang, X, Wang, Q, Cao, B, et al. Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant Enterobacteriaceae bacteremia. Antimicrob Agents Chemother 2019;63:e01511–e01518.Google ScholarPubMed
Kassem, A, Raed, A, Michael, T, et al. Risk factors and outcomes of patients colonized with carbapenemase-producing and non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae. Infect Control Hosp Epidemiol 2020;41:1154–1161.CrossRefGoogle ScholarPubMed
Bar-Yoseph, H, Cohen, N, Korytny, A, et al. Risk factors for mortality among carbapenem-resistant enterobacteriaceae carriers with focus on immunosuppression. J Infect 2019;78:101–105.CrossRefGoogle ScholarPubMed
Weiss, SL, Fitzgerald, JC, Balamuth, F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med 2014;42:2409–2417.CrossRefGoogle ScholarPubMed
Ferrer, R, Martin-Loeches, I, Phillips, G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749–1755.Google ScholarPubMed
Zhang, D, Micek, ST, Kollef, MH. Time to Appropriate antibiotic therapy is an independent determinant of postinfection icu and hospital lengths of stay in patients with sepsis. Crit Care Med 2015;43:2133–2140.CrossRefGoogle ScholarPubMed
Bartsch, SM, McKinnell, JA, Mueller, LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23:48.e49–48.e16.CrossRefGoogle Scholar
Supplementary material: PDF

Kengkla et al. supplementary material

Tables S1-S4

Download Kengkla et al. supplementary material(PDF)
PDF 362.2 KB